AtriCure (NASDAQ:ATRC – Free Report) had its price objective lifted by BTIG Research from $45.00 to $55.00 in a report released on Monday morning, MarketBeat.com reports. They currently have a buy rating on the medical device company’s stock.
Other equities research analysts have also recently issued reports about the stock. Citigroup reissued a “market outperform” rating on shares of AtriCure in a research report on Tuesday, July 21st. Zacks Research raised shares of AtriCure from a “hold” rating to a “strong-buy” rating in a research note on Friday, July 24th. Weiss Ratings upgraded shares of AtriCure from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, August 19th. Wall Street Zen lowered shares of AtriCure from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 2nd. Finally, Raymond James Financial set a $52.00 price objective on shares of AtriCure in a research note on Tuesday, July 21st. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, AtriCure presently has an average rating of “Moderate Buy” and a consensus target price of $48.62.
Check Out Our Latest Research Report on ATRC
AtriCure Stock Performance
AtriCure (NASDAQ:ATRC – Get Free Report) last posted its quarterly earnings results on Thursday, July 23rd. The medical device company reported $0.18 EPS for the quarter. AtriCure had a return on equity of 2.34% and a net margin of 1.85%.The company had revenue of $153.60 million during the quarter, compared to analysts’ expectations of $151.80 million. During the same quarter in the previous year, the business earned ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. On average, research analysts predict that AtriCure will post 0.2 earnings per share for the current year.
Insider Buying and Selling at AtriCure
In other AtriCure news, Director Maggie Yuen sold 3,500 shares of AtriCure stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $38.42, for a total transaction of $134,470.00. Following the transaction, the director directly owned 14,015 shares of the company’s stock, valued at $538,456.30. The trade was a 19.98% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Sven Wehrwein sold 25,000 shares of AtriCure stock in a transaction that occurred on Tuesday, July 28th. The shares were sold at an average price of $37.84, for a total transaction of $946,000.00. Following the transaction, the director directly owned 40,518 shares in the company, valued at approximately $1,533,201.12. This trade represents a 38.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 53,616 shares of company stock worth $2,149,994. Company insiders own 4.00% of the company’s stock.
Hedge Funds Weigh In On AtriCure
A number of hedge funds have recently made changes to their positions in ATRC. Geneos Wealth Management Inc. purchased a new stake in AtriCure during the 2nd quarter worth $37,000. Smartleaf Asset Management LLC raised its position in AtriCure by 59.8% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,146 shares of the medical device company’s stock valued at $46,000 after purchasing an additional 429 shares during the period. Harbor Investment Advisory LLC purchased a new position in AtriCure in the second quarter valued at about $40,000. Allworth Financial LP acquired a new position in shares of AtriCure during the second quarter worth about $43,000. Finally, Fifth Third Bancorp acquired a new position in shares of AtriCure during the first quarter worth about $51,000. Hedge funds and other institutional investors own 99.11% of the company’s stock.
About AtriCure
AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.
The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.
Read More
- Five stocks we like better than AtriCure
- Williams-Sonoma’s Quarter Gave Bulls More Than Just a Beat-and-Raise
- Alcoa’s Gallium Project Opens a New Door Beyond Aluminum
- Oura’s $16 Billion IPO Could Put a New Price on Wearable Tech
- Can Tesla’s Flying Roadster Distract From Its Real Risks?
Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.
